Associated Papers
Combining Molecular Dynamics and Machine Learning to Predict Drug Resistance Causing Variants of BRAF in Colorectal Cancer.
Xie L et al.
Molecules (basel, Switzerland), 2025
Targeting Non-V600 Mutations in BRAF: A Single Institution Retrospective Analysis and Review of the Literature.
Chaudhary HA et al.
Drugs in R&d, 2024
Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer.
Tewari AK et al.
Cell Reports, 2021
Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making.
Abida W et al.
Jco Precision Oncology, 2017
Somatic BRCA2 bi-allelic loss in the primary prostate cancer was associated to objective response to PARPi in a sporadic CRPC patient.
Romero-Laorden N et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2017
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.
Dahlman KB et al.
Cancer Discovery, 2012
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.
Nikolaev SI et al.
Nature Genetics, 2011
Select a paper to view details